Shim, Hong Seok
Horner, James W.
Wu, Chang-Jiun http://orcid.org/0000-0001-8350-6397
Li, Jiexi http://orcid.org/0000-0003-1508-5732
Lan, Zheng D.
Jiang, Shan
Xu, Xueping
Hsu, Wen-Hao http://orcid.org/0000-0001-9050-8227
Zal, Tomasz
Flores, Ivonne I.
Deng, Pingna
Lin, Yuan-Ta
Tsai, Li-Huei http://orcid.org/0000-0003-1262-0592
Wang, Y. Alan http://orcid.org/0000-0001-8272-2450
DePinho, Ronald A. http://orcid.org/0000-0002-5625-577X
Article History
Received: 22 February 2021
Accepted: 29 October 2021
First Online: 20 December 2021
Competing interests
: The authors declare no competing interests specifically related to this work. R.A.D. is a founder, advisor and/or director of Tvardi Therapeutics, Nirogy Therapeutics, Stellanova Therapeutics, Sporos Bioventures and Asylia Therapeutics, which are focused on therapies for cancer, fibrosis and/or inflammation.